Europe EditionNew clinical trial aims to prevent relapse in patients with DLBCL
- The ALPHA3 trial investigates whether the CAR T cell product can prevent relapse in patients with DLBCL.
- The trial employs an investigational blood test to detect cancer signs earlier than traditional scans.
- Cema-Cel is administered after MRD detection to target remaining cancer cells and prevent relapse.
- The ALPHA3 trial focuses on early intervention to improve cure rates for DLBCL patients at high risk of relapse.
Insights by Ground AI
Does this summary seem wrong?
153 Articles
153 Articles
All
Left
7
Center
61
Right
11
The Norfolk Daily News+151 Reposted by 151 other sources
New clinical trial aims to prevent relapse in patients with DLBCL
(BPT) - For many patients diagnosed with diffuse large B-cell lymphoma (DLBCL), the first step in treatment is a standard regimen of chemotherapy. This approach cures most patients, but research shows that one in three will see their cancer return…
2nd Generation CAR T Shows Benefit
GLPG5101, a second-generation anti-CD19/4-1BB CAR T-cell therapy, shows high complete response rates in the treatment of high-risk indolent relapsed/refractory (r/r) non-Hodgkin lymphoma, with a notably shortened vein-to-vein time, or time from leukapheresis (the separation and collection of cells) to infusion, compared with other CAR T products. “The short vein-to-vein time of GLPG5101 eliminated the need […] The post 2nd Generation CAR T Shows…
Coverage Details
Total News Sources153
Leaning Left7Leaning Right11Center61Last UpdatedBias Distribution77% Center
Bias Distribution
- 77% of the sources are Center
77% Center
C 77%
14%
Factuality
To view factuality data please Upgrade to Premium
